• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Aura Biosciences Inc (NQ: AURA )

    7.560 +0.280 (+3.85%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 28, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,655,056
    Open 7.350
    Bid (Size) 7.530 (1)
    Ask (Size) 7.560 (7)
    Prev. Close 7.280
    Today's Range 7.250 - 7.580
    52wk Range 5.990 - 12.50
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    AURA Stock Earnings: Aura Biosciences Beats EPS for Q1 2024
    AURA stock results show that Aura Biosciences beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    AURA Stock Earnings: Aura Biosciences Beats EPS for Q4 2023
    AURA stock results show that Aura Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace

    Performance

    YTD
    -16.28%
    -16.28%
    1 Month
    +2.86%
    +2.86%
    3 Month
    -2.58%
    -2.58%
    6 Month
    -16.28%
    -16.28%
    1 Year
    -38.79%
    -38.79%

    More News

    Read More
    Recap: Aura Biosciences Q4 Earnings
    Via Benzinga
    Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
    From Aura Biosciences, Inc.
    Via Business Wire
    Aura Biosciences to Participate in Upcoming Investor Conferences
    From Aura Biosciences Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma
    From Aura Biosciences Inc.
    Via Business Wire
    Over $13M Bet On This Energy Stock? Check Out These 4 Stocks Insiders Are Buying
    Via Benzinga
    Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
    From Aura Biosciences, Inc.
    Via Business Wire
    Aura Biosciences to Participate in Upcoming Investor Conferences
    From Aura Biosciences Inc.
    Via Business Wire
    Why Aura Biosciences Stock Hit A New 52-Week Low Today
    Via Benzinga
    Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Why Alteryx Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Via InvestorPlace
    Sanmina, Adtran, Ameresco And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
    Via Benzinga
    Aura Biosciences Announces Pricing of Public Offering of Common Stock
    From Aura Biosciences, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Aura Biosciences Announces Proposed Public Offering of Common Stock
    From Aura Biosciences, Inc.
    Via Business Wire
    Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma
    From Aura Biosciences, Inc.
    Via Business Wire
    Top 5 Health Care Stocks That May Fall Off A Cliff This Month
    Via Benzinga
    Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023
    From Aura Biosciences Inc.
    Via Business Wire
    Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments
    From Aura Biosciences Inc.
    Via Business Wire
    Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
    From Aura Biosciences Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.